On October 2, 2025, Xilio Therapeutics, Inc. announced its approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective October 6, 2025. The company has until March 30, 2026, to regain compliance with the $1.00 minimum bid price requirement to avoid further delisting.